secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001213900-26-007794
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech extends Meteora FPA valuation to Dec 2026, adds $372k AlpineBrook debt
--------------------------------------------------------------------------------

- Eighth FPA amendment with Meteora extends Valuation Date to December 31, 2026.
- AlpineBrook Second Amendment increases secured note principal by $372,000 to $26,507,106.
- Interest on the new $372,000 loan accrues from January 23, 2026.
- Borrowers agree to use best efforts to negotiate convertible loan consolidation with AlpineBrook.
- Borrowers must give AlpineBrook 24-hour pre-review of any public disclosure involving the lender.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026007794/0001213900-26-007794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026007794/ea0273451-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-007794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer